The global high potency active pharmaceutical ingredients market size is expected to be worth around US$ 44.8 billion by 2030, according to a new report by Vision Research Reports.
The global high potency active pharmaceutical ingredients market size is expected to be worth around US$ 44.8 billion by 2030, according to a new report by Vision Research Reports.
The global high potency active pharmaceutical ingredients market size was valued at US$ 24.4 billion in 2020 and is anticipated to grow at a CAGR of 20.3% during forecast period 2021 to 2030.
Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/37899
Growth Factors
Increasing number of new entrants producing fast relief therapeutics in emerging countries of India and China is anticipated to boost the demand for High potency active pharmaceutical ingredients (HPAPIs) over the forecast period.
In addition, supportive government regulations for commercialization and research and development of novel drug molecules are projected to drive the industry growth. Extensive capital investments required for development of production facility has lead to increase in contract manufacturing activities for HPAPIs during the forecast period.
Report Coverage
| Report Scope | Details |
| Market Size | USD 44.8 billion by 2030 |
| Growth Rate | CAGR of 20.3% From 2021 to 2030 |
| Base Year | 2021 |
| Historic Data | 2017 to 2020 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Product, Manufacturer,Drug Type, Application |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Mentioned | Lonza, Novartis International AG, BASF AG, Carbogen Amcis AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd Bristol-Myers Squibb, Pfizer Inc., Roche Diagnostics., Hospira Inc, Boehringer Ingelheim, Covidien Plc, Merck & Co, Bayer AG, Sigma-Aldrich Corporation, and Sanofi Aventis. |
Report Highlights
Segmentation of high potency API market on the basis of products is done in to synthetic and biotech. Synthetic molecules is considered to be the largest market in 2016 in terms of revenue share owing to the easier protocols for synthesis of these molecules coupled with higher availability of raw material. The biotech segment is expected to witness lucrative growth owing to the technological advancements in this segment and high level of efficacy of these ingredients.
Biotech products are expected to show significant growth during the forecast period owing to increasing demand for biologics and associated benefits such as minimum side effects and higher efficacy levels. In addition, shifting of consumer preference from synthetic to biotech molecules is factor attributing towards the higher penetration rate of biologics.
Biotech HPAPI mainly consists of drug molecules obtained after usage of molecular techniques such as recombinant DNA technology. The genes expressing these molecules are transferred into expression vector for synthesis of the higher amount of drug molecule in less time.
Biotech HPAPI is mostly peptides and other forms of enzymes. The market for Biotech HPAPI is expected to witness lucrative growth owing to the technological advancements in this segment and high level of efficacy of these ingredients.
Increasing incidence of chronic disorders such as cancer and others along with patent expiration of blockbuster drugs thereby boosting generics drug manufacturing. Rising demand for biotech synthesis drugs and introduction of innovative therapeutics are the key factors favoring competitive growth.
Incorporation of continuous process technology for the production of petrochemicals and polymers are further contributing toward the market growth. Emergence of multiple separation technology including filtration, purification and fermentation processes with advanced technology to provide growth platform to this market over the forecast period.
Manufacturers in High potency API include in-house and outsourced. In-house market dominated the overall industry in terms of revenue share owing to the higher availability of raw material and intensive capitalization of major key players in development of high end manufacturing facility. HPAPI molecules are manufactured by some pharmaceutical companies in their own manufacturing facilities. Pharmaceutical companies have made huge amount of investments in developing in house capabilities and specialized requirements for in house HPAPI investments.
Contract manufacturing services are also increasing in this field and are expected to witness lucrative growth.Contract manufacturing and outsourcing of HPAPI molecule development is growing trend in pharmaceutical sector. Companies such as Evonik and Lonza are actively involved in providing contract manufacturing services to other companies.Introduction of advancements in manufacturing technology such as single use production and batch culture fermentation for separating molecules is anticipated to offer opportunities for contract manufactures in coming years.
HPAPI drugs are segmented as innovative and generic. Innovative drugs segment dominated the drug type in terms of revenue share owing to the rising research and development activities for novel drug development coupled with favorable government initiatives. Expiration of patents of branded drug molecules is expected to increase the growth of generic drugs over the forecast period.
Established R&D facilities, increasing amount of funding and favorable regulatory structure are key factors for growth of innovative HPAPI market. Owing to extensive research in this field many novel innovative products are in pipeline and are expected to launch in the forecast period.
New entrants in this segment are expected to fuel the growth of this market. Introduction of advancements in the manufacturing of novel molecules with better efficacy and lower dosage for cancer treatment is another factor contributing toward the segment growth.
Patent expiry of branded drug molecules is primary factor attributing to lucrative growth of generic HPAPI drugs. Generic drug market is expected to show lucrative growth in countries such as India and Brazil owing to presence of unmet clinical needs in this area and high acceptance levels for OTC drugs.
HPAPI are used majorly in treatment of hormonal imbalance, oncology, glaucoma and others. Oncology segment dominated the overall industry owing to the rising cancer incidences worldwide. Cancer is estimated to be second most common cause for mortality in the U.S. Extensive R&D is also undertaken by many companies for development of drugs specific to novel biomarkers. These molecules are also widely used in Antibody Drug Conjugates (ADCs) form which is an effective and important development in the field of cancer treatment.
Hormonal followed oncology owing to increasing hormonal imbalance cases mainly in female population. Sedentary lifestyle has increased prevalence of metabolic disorders. Hormonal imbalance is growing concern in majority of countries. The disorders include sexual hormone imbalance and thyroid problems.
Glaucoma is primarily caused due to increase in blood sugar levels. Increasing lifestyle changes and growing obese population are key factors increasing the usage of glaucoma drugs.The applications of HPAPIs are developing in the treatment of neurological, cardiovascular and musculoskeletal drugs. These molecules are also find applications in certain gynecological, high potency analgesics, and cosmetic applications.
North America recorded the largest revenue of the overall industry as of 2020. The growth is primarily due to the rising chronic disease patients coupled with increasing demand for fast acting and higher efficacy drugs. Furthermore, increasing awareness pertaining to highly potent drugs, rising demand for anti-cancerous therapeutics and growing number of biotechnology industries are the factors attributing to dominant share.
North America have highly regulated and developed pharmaceutical industry. Incidence of cancer is higher, in this region hence, cancer therapy drugs show lucrative growth and is expected to be the same during the future period. Increasing incidence of older age diseases with changing lifestyle are the key contributing factors for growing demand for HPAPIs in this region.
The U.S. held the dominant market share of high potency APIs in North America. The key industry players holding majority of market share in this region are SAFC, Teva Pharmaceuticals, Bristol Myers Squibb, Cambrex Ferro, and Carbogen Amcis.
Asia Pacific region is expected to register high growth owing to the flourishing generic drug market, developing healthcare infrastructure and presence of untapped opportunities. Growing investments in biotechnology sector, supportive government initiatives and rapidly growing oncology market are the factors expected to propel the industry growth in this region.
In addition, growing generic sector business and improving healthcare facilities is anticipating the further growth in the near future. Healthcare infrastructure is growing rapidly in Asian countries, especially in India & China. The demand for oncology drugs & is expected to fuel the market growth over the forecast period.
Key Players
Lonza, Novartis International AG, BASF AG, Carbogen Amcis AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd Bristol-Myers Squibb, Pfizer Inc., Roche Diagnostics., Hospira Inc, Boehringer Ingelheim, Covidien Plc, Merck & Co, Bayer AG, Sigma-Aldrich Corporation, and Sanofi Aventis.
Related Reports
- Generic Pharmaceuticals Contract Manufacturing Market Report 2022-2030 - https://www.visionresearchreports.com/generic-pharmaceuticals-contract-manufacturing-market/39887
- Pharmaceutical Dissolution Testing Services Market Report 2022-2030 - https://www.visionresearchreports.com/pharmaceutical-dissolution-testing-services-market/39725
- High Potency API Contract Manufacturing Market Report 2022-2030 - https://www.visionresearchreports.com/high-potency-api-contract-manufacturing-market/39378
Market Segmentation
- Product Outlook
- Synthetic
- Biotech
- Manufacturer Outlook
- In-house
- Outsourced
- Drug Type Outlook
- Innovative
- Generic
- Application Outlook
- Oncology
- Hormonal
- Glaucoma
- Others
- Regional Outlook
- North America
- Europe
- Asia Pacific
- Latin America
- The Middle East and Africa
Click Here to View Full Report Table of Contents
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/checkout/37899
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333